Search

Your search keyword '"Daniel J. Crona"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Daniel J. Crona" Remove constraint Author: "Daniel J. Crona"
84 results on '"Daniel J. Crona"'

Search Results

1. Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform

3. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients

4. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors

6. The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study

7. The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents

9. Data from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib

10. Figure S3 from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib

12. Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients

13. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

14. Tolerability of palbociclib in younger and older patients with advanced breast cancer

15. Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia

16. Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model

17. Abstract 6281: OTX-015 inhibits proliferation and migration in ARID1A-mutated bladder cancer

18. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients

19. KDR genetic predictor of toxicities induced by sorafenib and regorafenib

20. Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab-Induced Hypertension in Cancer Patients (Alliance)

21. Abstract B030: Combined inhibition of BET proteins and PARP promotes impaired DNA damage repair response and cell cycle dysregulation in preclinical models of bladder cancer

22. Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID-19 pandemic

23. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors

24. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

25. Targeting an EGFR Water Network with 4‐Anilinoquin(az)oline Inhibitors for Chordoma

26. Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines

27. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)

28. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer

30. Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents

31. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know?

32. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients

33. Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains

34. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients

35. Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints

38. Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

39. An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance)

40. Design and evaluation of novel 4-anilinoquinolines and quinazolines EGFR inhibitors in lung cancer and chordoma

41. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib

42. Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS)

43. Application of a Tacrolimus Population Pharmacokinetic Model to Adult Allogeneic Hematopoietic Stem Cell Transplant Patients

44. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study

45. Abstract 1743: Evaluation of the effects of combined chemical inhibition of PARP and BET proteins in preclinical models of urothelial bladder cancer

46. Direct oral anticoagulants in extremely obese patients: OK to use?

47. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy

48. Genetic Variants of

49. Statin use and survival in patients with metastatic castrationresistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: The international retrospective observational STABEN study

50. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance

Catalog

Books, media, physical & digital resources